Dr. Reddy's Laboratories Limited has announced that certain batches of its semaglutide product were found to be out of specification due to an issue with the active pharmaceutical ingredient (API) used. The company is investigating the root cause and implementing corrective measures. Commercial supplies of the product will be delayed until the issue is resolved. Dr. Reddy's has stated that this issue does not impact patient safety or existing global regulatory filings, and they remain committed to ensuring reliable global supplies of this important metabolic therapy. To discuss this matter and address queries, the company's management will host a conference call on Thursday, July 9, 2026, from 16:30 to 17:00 IST (07:00 – 07:30 ET). Participants can pre-register via a provided Zoom link. The audio link and transcript will be available on the company's website.
